Gain Therapeutics (GANX)
NASDAQ:GANX

Gain Therapeutics Stock Analysis & Ratings

Gain Therapeutics Stock Analysis Overview

Smart Score
4
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Gain Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

GANX

GANX Stock Stats

Previous Close$4.86
Open$4.81
Bid0 x 0
Ask0 x 0
Today’s Range$4.65 - $5
52-Week Range$4.65 - $17.93
Volume64.55K
Average Volume73.85K
Market Cap$55.60M
Beta-1.19
P/E Ratio-3.5
EPS-1.33
Earnings DateNov 12, 2021

Company Description

Gain Therapeutics

Gain Therapeutics Inc is a development-stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (LSDs), including rare genetic diseases and neurological disorders. Its pipeline includes the GLB1 gene, GBA1 gene, IDUA gene, and GALC gene.
Sector
Healthcare
Industry
Biotechnology
CEO
Eric I. Richman
Employees
16
Website
www.gaintherapeutics.com
ISIN
US36269B1052
Address
4800 Hampden Lane, Bethesda, MD, 20814, US

Financials


P/E Ratio Range

Currently, no data available
Please return soon. This page is being updated.
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

GANX FAQ

What was Gain Therapeutics’s price range in the past 12 months?
Gain Therapeutics lowest stock price was $4.65 and its highest was $17.93 in the past 12 months.
    What is Gain Therapeutics’s market cap?
    Gain Therapeutics’s market cap is $55.60M.
      What is Gain Therapeutics’s price target?
      The average price target for Gain Therapeutics is $25.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $30.00 ,the lowest forecast is $21.00. The average price target represents 444.87% Increase from the current price of $4.68.
        What do analysts say about Gain Therapeutics?
        Gain Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Gain Therapeutics’s upcoming earnings report date?
          Gain Therapeutics’s upcoming earnings report date is Nov 12, 2021 which is 65 days ago.
            How were Gain Therapeutics’s earnings last quarter?
            Gain Therapeutics released its earnings results on Aug 11, 2021. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.266 by -$0.034.
              Is Gain Therapeutics overvalued?
              According to Wall Street analysts Gain Therapeutics’s price is currently Undervalued.
                Does Gain Therapeutics pay dividends?
                Gain Therapeutics does not currently pay dividends.
                What is Gain Therapeutics’s EPS estimate?
                Gain Therapeutics’s EPS estimate is -$0.39.
                  How many shares outstanding does Gain Therapeutics have?
                  Gain Therapeutics has 11,880,000 shares outstanding.
                    What happened to Gain Therapeutics’s price movement after its last earnings report?
                    Gain Therapeutics reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.266. Following the earnings report the stock price went up 14.439%.
                      Which hedge fund is a major shareholder of Gain Therapeutics?
                      Among the largest hedge funds holding Gain Therapeutics’s share is Greenlight Capital Inc. It holds Gain Therapeutics’s shares valued at 4M.

                        What's Included in PREMIUM?
                        Make informed decisions based on Top Analysts' activity
                        Know what industry insiders are buying
                        Get actionable alerts from top Wall Street Analysts
                        Find out before anyone else which stock is going to shoot up
                        Get powerful stock screeners & detailed portfolio analysis